Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Neoplasm Metastasis 2Glioma 2Glioblastoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Nasopharyngeal Carcinoma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinosarcoma 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 162Carboplatin 144Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 38Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × LY-2157299 × Clear all
NCT02672475 2023-11-22

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
29 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡